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ERK1,2The present study evaluated the role of interleukin (IL) 17 in multilineage commitment of C2C12 myoblastic
cells and investigated associated signaling pathways. The results concerning the effects on cell function
showed that IL-17 inhibits the migration of C2C12 cells, while not affecting their proliferation. The data re-
garding the inﬂuence on differentiation demonstrated that IL-17 inhibits myogenic differentiation of C2C12
cells by down-regulating the myogenin mRNA level, myosin heavy chain expression and myotube formation,
but promotes their osteogenic differentiation by up-regulating the Runt-related transcription factor 2 mRNA
level, cyclooxygenase-2 expression and alkaline phosphatase activity. IL-17 exerted these effects by activat-
ing ERK1,2 mitogen activated protein kinase signaling pathway, which in turn regulated the expression of
relevant genes and proteins to inhibit myogenic differentiation and induce osteogenic differentiation. Addi-
tional analysis showed that the induction of osteogenic differentiation by IL-17 is independent of BMP signal-
ing. The results obtained demonstrate the potential of IL-17 not only to inhibit the myogenic differentiation of
C2C12 myoblasts but also to convert their differentiation pathway into that of osteoblast lineage providing
new insight into the capacities of IL-17 to modulate the differentiation commitment.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Interleukin (IL) 17A is the prototypemember of a newly deﬁned and
intensively investigated family of proinﬂammatory cytokines mainly
produced by Th17 cells. Signature roles of IL-17 in inﬂammation and
immune response are mediated by the release of CXC chemokines,
proinﬂammatory and hematopoietic cytokines and antimicrobial pep-
tides [1–3]. IL-17 induces neutrophil and granulocyte expansion, as
well as neutrophil recruitment, leading to tissue inﬂammation [4–7].
Moreover, increasing evidence indicates that IL-17, within a complex
network of interactive cytokines, contributes to the pathogenesis of var-
ious autoimmune and inﬂammatory diseases [1–3].
IL-17 family members signalize through a family of unique cognate
receptors, which belong to type I transmembrane proteins [8]. The sig-
naling downstream of IL-17 receptor (IL-17R) implicates activation of
protein kinase A (PKA), mitogen-activated protein kinase (MAPK),
janus kinase/signal transducer and activator of transcription (JAK/STAT)
and nuclear factor-kappaB (NF-kB) cascades [8]. Even though IL-17 is
considered to be secreted exclusively by Th17 cells, many cell types in
the body express IL-17R, thus becoming potential targets of IL-17.earch, University of Belgrade,
5 788; fax: +381 11 2643 691.
l rights reserved.Previously, our group postulated IL-17 as an important regulator of
hematopoietic progenitor cell activity which affects granulopoiesis and
erythropoiesis, suggesting its role in cell proliferation and differentiation
[5,6,9,10]. As different cell types appear to respond differently to IL-17,
novel functions concerning cell differentiation have been recently dis-
covered for this cytokine. IL-17 induces osteogenic differentiation of
human mesenchymal stem cells (MSCs) [11], implying its involvement
in bone turnover; while, it inhibits adipogenic differentiation of human
bone marrow MSCs and enhances lipolysis in differentiated adipocytes
[12]. Also, some reports implicate IL-17 in cell proliferation, as a growth
factor for both human and mouse MSCs [11,13]. IL-17's involvement in
cell differentiation is an issue that has just started to be explored, with
diverse implications. In respect to this, some pathological states, such
as inﬂammatory muscle and bone diseases, involve inﬁltration of Th17
cells and elevated levels of IL-17 in the tissue [2,14,15]. Although higher
expression of IL-17 has been observed inmuscle samples in inﬂammato-
ry myopathies [14], the effect of IL-17 on myogenic differentiation is yet
unknown.
This study was undertaken to investigate the potential of IL-17 to
modulate the differentiation of myoblastic cell line C2C12 and to eluci-
date the signaling pathways involved. Namely, C2C12 myoblasts under
myogenic culture conditions differentiate into myotubes rapidly, pro-
ducing characteristic muscle proteins, but are also capable to shift dif-
ferentiation pathway from myoblastic to osteoblastic within the
appropriate osteogenic culture conditions [16–19]. Moreover, C2C12
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posed as ‘multiblasts’ (multiple tissue blasts) byWada et al. [18]. Hence,
this cell line is widely used for studying mechanisms of speciﬁc lineage
differentiation and commitment [18,20]. In this work we examined the
ability of IL-17 tomodulate the expression of speciﬁc genes and proteins
in C2C12 cells related to myogenic and osteogenic differentiation as
well aswhether IL-17 affects the cell proliferation andmigration. To ex-
plore the signaling pathways underlying IL-17-induced events, we ana-
lyzed the involvement of MAPKs, since numerous reports indicate that
these signaling molecules, speciﬁcally ERK1,2 and p38, are implicated
in the signaling elicited by IL-17 in various cell types [1,3,19,21]. Given
that bonemorphogenetic proteins (BMPs) are strong osteogenic induc-
tors in C2C12 cells [16,20], we further aimed to elucidate whether
IL-17 may interact with BMP-Smad signaling during osteogenic
differentiation.
Results obtained demonstrate that IL-17 is capable of modulating
the multilineage commitment of C2C12 cells by inhibiting myogenic
and promoting, in a BMP-independent fashion, their osteogenic dif-
ferentiation through the activation of ERK1,2 MAPK.2. Materials and methods
2.1. Cell culture and differentiation
C2C12 cell line was purchased from American Type Culture Collec-
tion (ATCC, Rockville, MD, USA) and cultured in growth medium
(GM) consisting of DMEM (Sigma-Aldrich, St. Louis, MO, USA) sup-
plemented with 10% fetal bovine serum (FBS) (PAA Laboratories
GmbH, Pasching, Austria) in humidiﬁed environment at 37 °C and
5% CO2 in air. Myogenic differentiation was induced with myogenic
differentiation medium (MDM) consisting of DMEM with 2%
HS (PAA), while osteogenic differentiation was induced with
osteogenic differentiation medium (ODM) containing 50 μM
ascorbic acid (Sigma-Aldrich), 10 nM dexamethasone, 10 mM beta-
glycerophosphate, both from Applichem (Darmstadt, Germany), and
10% FBS in DMEM. Both myogenic and osteogenic differentiation of
cells was induced during a period of six days. Selective signal trans-
duction inhibitors of MEK1,2-ERK1,2 (PD98059) and p38
(SB203580), obtained from Calbiochem (Darmstadt, Germany),
were used at 25 μM and 10 μM, respectively.2.2. Proliferation assay
Proliferation rate of C2C12 cells was analyzed by MTT test. 5×103
cells/well were seeded in 96-well plates in GM. The following day GM
was replaced with fresh GM, MDM or ODM and the cultivation was
continued for 48 h in the presence of 0, 25, 50 and 100 ng/ml recom-
binant mouse (rm) IL-17 (R&D Systems, Minneapolis, MN, USA). After
this period, MTT (Sigma-Aldrich) was added to cells at 0.5 mg/ml, and
after 2 h the formazan crystals were dissolved in 0.1 N HCl in isopro-
panol. The absorbance was read at 530 nm.2.3. Scratch assay
The motility of C2C12 cells was analyzed by in vitro scratch assay.
Cells were seeded in a 24-well plate in GM. When cells reached con-
ﬂuence, a scratch in the monolayer over the total diameter of each
well was made using a sterile pipette tip, and cell cultures were
allowed to grow for 24 h in GM with 0, 25, 50 and 100 ng/ml rmIL-
17. The cells were then ﬁxed with ice-cold methanol and stained
with 0.1% crystal violet. Migration of the cells into the scratch area
was documented by light microscopy and quantiﬁed by TScratch soft-
ware (Computational Science and Engineering Laboratory, Swiss Fed-
eral Institute of Technology, ETH Zurich, Zurich, Switzerland).2.4. Immunoﬂuorescence assay
Immunoﬂuorescent labeling was used to detect IL-17R in C2C12
cells. Cells were seeded over rounded cover slips in GM and grown
over night. After being ﬁxed with 4% formaldehyde in PBS, cell
monolayers were incubated with anti-IL-17R antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), followed by incubation with
anti-rabbit-FITC secondary antibody and 1 μg/ml DAPI (both from
Sigma-Aldrich). The samples were examined and photographed
using an epi-ﬂuorescence microscope.
2.5. Myosin heavy chain (MyHC) detection
To conﬁrm myogenic differentiation of the cells, we examined the
presence of MyHC by immunocytochemistry. Followingmyogenic dif-
ferentiation cells were ﬁxed with ice-cold methanol and blocked with
4% bovine serum albumin (BSA) (Sigma-Aldrich) in PBS for 30 min at
37 °C. The cells were then incubated for 1 h at room temperature with
primary antibody against MyHC,α-MF-20, from Developmental Stud-
ies Hybridoma Bank (University of Iowa, Iowa City, IA, USA), followed
by incubation for 1 h at room temperature with secondary, HRP-
conjugated anti-mouse antibody (Sigma-Aldrich). Finally, cells were
incubated with a developer (0.6 mg/ml DAB from Sigma-Aldrich and
0.1% H2O2 in PBS) and examined under a light microscope to detect
bound HRP.
2.6. Alkaline phosphatase (ALP) activity
ALP activity was used to demonstrate the level of osteogenic dif-
ferentiation of C2C12 cells. Following differentiation the cells were
ﬁxed with formalin/ethanol (1:9) for 30 s at room temperature, and
stained for ALP activity with alkaline phosphatase chromogen BICP/
NBT (5-bromo-4-chloro-3-indolyl phosphate/p-nitroblue tetrazolium
chloride) from Sigma-Aldrich. The reaction was stopped with 10 mM
NaF in PBS. The cells were then examined using a light microscope.
2.7. Western blot assay
Antibodies against pERK1,2, ERK1,2, pp38, p38, pJNK and JNK were
purchased from R&D Systems and antibodies against IL-17R,
cyclooxygenase-2 (COX-2), phospho-Smad1 and Smad1 were obtained
from Santa Cruz Biotechnology. Mouse monoclonal anti-HA antibody
was kindly provided by Dr Carmelo Bernabeu (CIB, Spain). Cells were
collected after cultivation and adequate treatment, as indicated in
Results, and total protein extractswere isolated using lysis buffer. Protein
samples from cell lysates were separated by SDS-PAGE and electrotrans-
ferred onto a nitrocellulose membrane. Membranes were blocked with
4% BSA in 0.5% Tween-20 in TBS and then incubated with primary anti-
bodies against IL-17R, ERK1,2, p38, JNK, MyHC or COX-2, as speciﬁed in
Results. Secondary antibodies conjugated with HRP (Sigma-Aldrich)
were used to detect the immune complexes by enhanced chemilumines-
cence. Labeled proteins were visualized with enhanced chemilumines-
cence reagent system from Applichem (Darmstadt, Germany). Protein
bands were quantiﬁed by densitometric scanning, using ImageMaster
TotalLab Version 1.11 software (Amersham Biotech).
2.8. RT-PCR
After corresponding cell treatments, total RNA was obtained using
TRIzol (Applichem) and complementary DNA was generated by the
SuperScript First-Strand Synthesis System for RT-PCR from Invitrogen
(Carlsbad, CA, USA), using oligo (dT) as a primer. PCR products were
obtained after 30 and 35 cycles of ampliﬁcation with an annealing
temperature of 52 °C. Beta-actin primer was from R&D Systems and
GAPDH, myogenin and IL-17R primers were from Invitrogen. Beta-
actin or GAPDH was ampliﬁed as a control for the amount of cDNA
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myogenin were: forward 5′-GGTGGAGAGCAACTCCAAAA-3′, reverse
5′-AAACAACGTAGGTGCCGAAG-3′ and forward 5′-TTTCTACCAG-
GAGCCCCACTT-3′, reverse 5′-TGATGGCTTTTGACACCAAC-3′ [19],
respectively. The intensity of the bands was quantiﬁed using
NIH-Image J software.
2.9. Transient transfections and reporter gene measurements
The MAPK/ERK reporter (SRE-luc) was provided by Dr. Angel Corbí
(CIB-CSIC, Spain); pSRE-luc contains two copies of the c-fos SRE (nucle-
otides−357 to−275, containing both an SRF binding site and an adja-
cent Ets motif) upstream of a minimal Tk promoter and the luciferase
gene. Myogenin promoter (G133-luc) was kindly provided by
Dr. Zhenguo Wu (Hong Kong University of Science & Technology,
Hong Kong, China); Runt-related transcription factor 2 (Runx2/Cbfa1)
reporter (p6OSE2-luc, containing 6 response elements followed by the
luciferase gene) [22] was kindly provided by Dr. Gerard Karsenty (Co-
lumbia University Medical Center, NY, USA). Constitutive active
MEK1-HA tagged construct (pECE/HAMAPKK S218D/S222D)was kind-
ly provided by Dr. Jacques Pouyssegur (University of Nice-Sophia Anti-
polis, France). pBRE-luc construct was kindly provided by Dr. P. ten
Dijke (Leiden University Medical Center, RC Leiden, The Netherlands).
The construct contains regions of the mouse Id1 promoter, important
for the induction of Id1 transcription factor by BMPs, fused to a lucifer-
ase reporter gene [23]. Constitutively active (ca, Q207D) and kinase-
dead (kd, K233R) ALK2 cloned into pCMV5 were kindly provided by
Dr. C. Vary (Northwestern University, Chicago, USA) and described by
Romero et al. [24]. For Smad1 transactivation assay, plasmids encoding
Gal4-Smad1, kindly provided by Dr. K. Nakayama (University of Tokyo
School of Medicine, Tokyo, Japan), were co-transfected with the Gal4-
luciferase reporter pFr5-Luc (Stratagene, La Jolla, CA).
C2C12 cells were grown in a 24-well plate (~2×105 cells/well) in
DMEM supplemented with 10% FBS. After reaching approximately 70%
conﬂuence, cells were transfected using Superfect transfection reagent
(Qiagen, Hilden, Germany) with 500 ng/well of each speciﬁc luciferase
construction and 25 ng/well of SV40-β-Gal as an internal control for
transfection efﬁciency. Six hours after transfection, the cells were fed
with fresh medium (DMEM with 10% FBS) and incubated overnight.
Transfected cells were then treated for 48 h, as indicated in speciﬁc ex-
periments. Cell extracts were then prepared and luciferase assays were
done using the Luciferase Assay System (Promega, Madison, WI, USA).
Luciferase activities were normalized with respect to parallel beta-
galactosidase activities, to correct for differences in transfection efﬁ-
ciency. Beta-galactosidase assays were performed using the Galacto-
Light Plus System from Tropix (Bedford, MA, USA).
2.10. Statistical analysis
The results shown are representative of at least three independent
experiments. Data are given as means±SEM. Statistical signiﬁcance
was evaluated using the Student's t-test. Differences were considered
to be signiﬁcant at a value of pb0.05.
3. Results
3.1. IL-17 inhibits migration without affecting the proliferation of C2C12
cells
Initially we elucidated whether C2C12 cells express IL-17 receptor.
When labeledwith anti-IL-17R antibody, a discrete positive punctuated
pattern, typical for membrane cell receptors, was noticed at the surface
of C2C12 cells (Fig. 1Aa), in comparison to the cells labeled with the
control antibody (Fig. 1Ab). The expression of IL-17R was further con-
ﬁrmed by Western blot assay (Fig. 1B), as well as by RT-PCR (Fig. 1C).Next, we determined the effect of IL-17 on the proliferation and
migration of C2C12 cells. As determined by MTT test, IL-17 treatment
did not alter the proliferation of C2C12 cells, neither when the cells
were cultured in plain growth medium, nor in myogenic or osteogen-
ic differentiation medium (Fig. 2A). As expected, due to the induction
of differentiation, the change from GM to differentiation media itself
produced a reduction in C2C12 cell proliferation, with stronger reduc-
tion noticed in cells grown in MDM.
The motility of C2C12 cells was also tested, using the in vitro scratch
assay. Cells grown inGMdisplayed highmigration capacity, since after a
period of 24 h of incubation they almost completely colonized the
scratch. During the same period of time, treatment with IL-17 inhibited
C2C12 cell migration in a dose dependent manner (Fig. 2B).
3.2. IL-17 inhibits myogenic differentiation of C2C12 cells
To analyze whether IL-17 affects C2C12 myogenic differentiation,
cells were induced to differentiate by cultivation in MDM for six
days, after which the formation of myotubes immunostained for
MyHC, a marker protein involved in terminal myogenic differentia-
tion [17–19], was evaluated. As shown in Fig. 3A, the number of
MyHC positive myotubes after IL-17 treatment was signiﬁcantly
lower, indicating that myogenic differentiation was inhibited by IL-
17 in a dose-dependent manner. This result was further supported
by Western blot analysis for MyHC, as in IL-17 treated cells grown
in MDM, the expression of MyHC was reduced and its level was com-
parable to the level detected in C2C12 cells prior to myogenic differ-
entiation (Fig. 3B). Moreover, RT-PCR analysis of myogenin, a
transcription factor required for myogenic differentiation [17–19],
demonstrated that the expression of myogenin mRNA transcript
markedly decreased in differentiated C2C12 cells after IL-17 treat-
ment, being at approximately the same level as in the cells grown in
GM before the induction of differentiation (Fig. 3C). This was further
conﬁrmed after the transfection of C2C12 cells with a myogenin re-
porter (G133-luc), when the addition of IL-17 to the medium induced
signiﬁcant inhibition of myogenin promoter transactivation (Fig. 3D).
3.3. IL-17 induces osteogenic differentiation of C2C12 cells
Since C2C12 cells were inhibited from differentiating to myotubes
by IL-17, our next goal was to determine whether the cells were di-
rected to differentiate into another cell lineage. Considering recent re-
port which demonstrated that IL-17 induces osteogenic
differentiation of MSCs [11], we analyzed the involvement of IL-17
in osteogenic differentiation of C2C12 cell line. Cells were cultured
in ODM, with or without IL-17, and after 6 days subjected to ALP de-
termination. As shown in Fig. 4A, osteogenic differentiation induced
by speciﬁc ODM was additionally stimulated by IL-17. We next
aimed to elucidate the degree at which the effect of IL-17 on osteo-
genic differentiation was dependent of the osteogenic factors present
in the culture medium. For this purpose, C2C12 cells were cultured in
MDM, since this medium is supplemented with only 2% HS and de-
prived of any other culture supplements, including osteogenic ones.
After six days in these culture conditions, as expected, the cells cul-
tured in the absence of IL-17 were completely negative for ALP cytos-
tain and the myotubes could be observed. However, after the IL-17
treatment, ALP positive colonies were detected, without visible myo-
tubes (Fig. 4A). The appearance of this early phenotypic marker for
osteogenic differentiation implied that the effect of IL-17 on the oste-
ogenic commitment of C2C12 cells was independent of the induction
media used. Therefore, we additionally evaluated the expression of
COX-2, protein involved in osteogenic differentiation [25], in C2C12
cells grown in MDM, and detected a dose-dependent increase of its
expression after IL-17 treatment, thus, conﬁrming the stimulatory ef-
fect of IL-17 on osteogenic differentiation (Fig. 4B). Furthermore,
when C2C12 cells were transfected with an osteogenic reporter
Fig. 1. IL-17 receptor is expressed in C2C12 cells.(A) C2C12 cells immunostained with IL-17R antibody and anti-rabbit FITC (a), isotype control antibody (b) and DAPI (c and d); cells
were examined using an immunoﬂuorescence microscope (400× magniﬁcation). (B) IL-17R expression detected in protein samples from C2C12 cell lysates after Western blot
assay; α-tubulin was used as a loading control. (C) The expression of IL-17R determined by RT-PCR analysis; GAPDH was used as a gel loading control.
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tor in osteogenic differentiation [26], signiﬁcant elevation in the
Runx2/Cbfa1 reporter transactivation was observed in transfected
cells treated with IL-17 (Fig. 4C).3.4. IL-17 activates MAPKs signaling in C2C12 cells
Next, we aimed to elucidate the signaling events triggered by IL-
17 in C2C12 cells. To determine whether IL-17 activates MAPKs,
growth-arrested cells were incubated with IL-17 for various time
points and cell lysates were then analyzed for the expression of phos-
phorylated p38, JNK and ERK1,2 MAPKs. The results shown in Fig. 5A
demonstrate signiﬁcantly increased phosphorylation of ERK1,2 MAPK
after treatment with IL-17 from 30 min after stimulation onwards.
Additionally, increased levels of phosphorylated p38 were observed,
with peak activation at 30 and 60 min after IL-17 treatment. In con-
trast, no expression of phosphorylated JNK was observable for both
untreated and IL-17-treated C2C12 cells.Fig. 2. IL-17 inhibits migration without affecting the proliferation of C2C12 cells.(A) Prolifer
and ODM in the presence of 0, 25, 50 and 100 ng/ml IL-17 for 48 h. (B) Migration of C2C12 c
cells, and cells cultured in the presence of 0, 25, 50 and 100 ng/ml IL-17 in GM. The recoloni
the monolayer at zero time. Numbers shown represent the percentage of the scratch area cOur next goal was to determine whether MAPK signaling path-
ways mediate the IL-17-induced differentiation commitment of the
C2C12 cells. To reveal the involvement of MAPKs, C2C12 cells were
initially treated with speciﬁc pharmacological inhibitors of p38 and
MEK1,2-ERK1,2 pathways, prior to their exposure to IL-17 and subse-
quent induction of myogenic or osteogenic differentiation. The usage
of p38 speciﬁc inhibitor, SB203580, either alone or in combination
with IL-17, blocked both the myogenic and the osteogenic differenti-
ation of C2C12 cells (Fig. 5B), suggesting that p38 is involved as a
basal regulator of C2C12 differentiation to both mesenchymal line-
ages, disregarding the presence of IL-17. Therefore, we focused our
detailed experiments on ERK1,2 MAPK signaling. To conﬁrm the stim-
ulating effect of IL-17 on ERK1,2 MAPK phosphorylation, a transfec-
tion of C2C12 cells with MEK1,2 MAPK responsive reporter (SRE-
luc) was carried out. Cells were then treated with IL-17 for 48 h and
the transactivation of the reporter was measured by luminometry.
In accordance with the IL-17-induced enhanced phosphorylation of
ERK1,2 MAPK, IL-17 signiﬁcantly enhanced the transactivity of the
MAPK reporter, too (Fig. 5C).ation of C2C12 cells determined by MTT test after the cells were cultured in GM, MDM
ells analyzed by scratch assay: a scratch was made in the conﬂuent monolayer of C2C12
zation of the scratch by adjoining cells was documented after 24 h; C0, scratch made in
overed with migrating cells.
Fig. 3. IL-17 inhibits myogenic differentiation of C2C12 cells.MyHC expression in C2C12 cells cultivated in GM or MDM in the presence of different concentrations of IL-17 deter-
mined by (A) immunocytochemistry (dark colored cells) and (B) Western blot assay; α-tubulin was used as a loading control. (C) Myogenin expression determined by RT-PCR in
cells grown in GM or MDM with or without 100 ng/ml IL-17; β-actin was used as a gel loading control. Densitometric quantiﬁcation of the PCR bands is indicated at the top of im-
ages, expressed relative to untreated cells, to which an arbitrary value of 1 was given, ±SEM given in brackets. Representative results from three independent experiments are
shown. Signiﬁcant difference from the control (untreated cells) by t-test: ***pb0.001. (D) The transactivation of G133-luc myogenin reporter measured by luminometry in tran-
siently transfected C2C12 cells grown in GM or MDM with or without IL-17 (100 ng/ml). The values were normalized to those found in cells grown in control GM; RLU, relative
luciferase units. Signiﬁcant difference from the control (GM) by t-test: ***pb0.001.
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myogenesis and IL-17-induced stimulation of osteogenesis
The effect of MEK1,2 pharmacological inhibitor, PD98059, was then
examined in the IL-17-induced inhibition of C2C12myogenic differenti-
ation. As shown in Fig. 6A treatment of C2C12 cells with PD98059, in the
presence of IL-17, partially recovered the capacity of the cells to form
myotubes, visible after MyHC immunostaining. This result was further
conﬁrmed by Western blot analysis for MyHC expression, as C2C12
cells treated with PD98059, either in the presence or absence of IL-17,
expressed MyHC at a level comparable to the control cells grown in
MDM alone (Fig. 6B). In addition, after the cells were treated with
PD98059, the expression of myogenin transcription factor was reverted
to the level observed in C2C12 cells cultured in MDM before the addi-
tion of IL-17 (Fig. 6C). Further on, the MEK1,2 inhibitor reverted the
suppressive effect of IL-17 on G133-luc myogenin promoter transacti-
vation in C2C12 transfected cells (Fig. 6D).
The same PD98059 inhibitor was used to analyze the involvement
of ERK1,2 MAPK signaling in IL-17 induced stimulation of C2C12 oste-
ogenic differentiation. In order to exclude the inﬂuence of the osteo-
genic media and to determine the signaling pathways elicited solely
by IL-17, the cells were cultured in serum-deprived MDM. The data
obtained showed that IL-17-stimulated osteogenic differentiation
was reverted after the treatment of C2C12 with PD98059, since noALP positive colonies were observed when the cells were co-treated
with IL-17 (Fig. 7A). This result was further conﬁrmed when
PD98059 inhibited the enhancing effect of IL-17 on the transactiva-
tion of Runx2/Cbfa1 reporter in C2C12 cells (Fig. 7B).
To conﬁrm that ERK1,2 MAPK is directly involved in the induction
of osteogenic differentiation by IL-17, a constitutively active mutant
form of MEK1 (caMEK1) was used. First, as a positive control of
MEK1-ERK1,2 signaling, detection of SRE-luc reporter activation by
caMEK1 was performed (Fig. 7Ca) as well as Western blot analysis
of HA tagged MEK1 protein expression in transfected cells (Fig. 7Ca,
insert). Cells were then co transfected with caMEK1 (pECE/HA
MAPKK), or empty vector, and Runx2/Cbfa1 reporter (p6OSE2-luc)
and cultured in GM and MDM for 24 h. Ectopic expression of
caMEK1 highly increased Runx2/Cbfa1 activation, in both conditions,
suggesting that activation of ERK1,2 is the key event involved in the
activation of the Runx2/Cbfa1 transcription factor which, consequent-
ly, initiates osteogenic differentiation (Fig. 7Cb).
3.6. IL-17 induced osteogenic differentiation of C2C12 myoblasts is BMP
independent
BMP-Smad signaling pathway is known to be involved in the oste-
ogenic differentiation of myogenic progenitor cells [16,20,27]. As pre-
viously demonstrated, BMP9-induced osteogenic differentiation in
Fig. 4. IL-17 induces osteogenic differentiation of C2C12 cells.(A) ALP activity in C2C12 cells cultured in GM, ODM and MDM in the absence or presence of 100 ng/ml IL-17. (B) COX-
2 expression in cells cultured in MDMwith different concentrations of IL-17; α-tubulin was used as a loading control. (C) The transactivation of p6SE2-luc reporter for Runx2/Cbfa1
measured by luminometry after the cells were grown in GM or MDM with or without IL-17 (100 ng/ml). The values were normalized to those found in cells grown in control GM;
RLU, relative luciferase units. Signiﬁcant difference from the control (GM) by t-test: **pb0.01.
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[28]. Therefore, we further analyzed whether BMP-Smad signaling is
implicated in IL-17-induced osteogenic differentiation of C2C12 cells
by using plasmids containing a kinase-dead ALK2, acting as dominant
negative form [24], and constitutively active ALK2 mutant genes.
To validate the plasmids, a Western blot analysis of HA-tagged
ALK2 protein expression in transfected cells was conducted. Also, a
phosphorylated form of Smad1 was observed only in cells transfected
with caALK2 indicating its functionality (Fig. 8A).
To examine whether IL-17 interacts with BMP-Smad signaling,
C2C12 cells were co-transfected with either BRE-luc reporter plasmid
or Gal4-Smad1 system and two mutant ALK2 expressing plasmids.
The cells were then cultured in MDM with or without IL-17.
As shown in Fig. 8B and C, IL-17 did not activate Smads signaling,
as neither pBRE-luc nor Gal4-Smad1 activation was observed when
compared to basal levels. Only in cells transfected with caALK2 a
strong BMP-dependent Smads activation was achieved. Furthermore,
to establish whether the activation of Runx2/Cbfa1 transcription fac-
tor by IL-17 is independent of BMP, cells were co-transfected with
Runx2/Cbfa reporter and kdALK2 or caALK2 plasmids. Activation of
Runx2/Cbfa1 reporter was noted after IL-17 treatment, even in cells
transfected with kdALK2, conﬁrming that IL-17 induced osteogenic
differentiation of C2C12 cells was not dependent on BMP activation
(Fig. 8D). As expected, cells transfected with caALK2 showed high
transactivation of Runx2/Cbfa1 reporter plasmid (Fig. 8D).4. Discussion
Although IL-17, the signature Th17 cell cytokine, is known to reg-
ulate diverse biological activities in many somatic tissues, its func-
tional role in cell differentiation is poorly studied. In the current
study, we analyzed the involvement of IL-17 in C2C12 celldifferentiation into myogenic and osteogenic lineage, as well as the
signaling pathways implicated.
The inhibitory effect of IL-17 on myogenesis, associated with the
attenuated expression of proteins and genes relevant for muscle dif-
ferentiation is a novel regulatory role of IL-17, demonstrated for the
ﬁrst time in our study. Considering the fact that the differentiation
of skeletal muscle cells is critically regulated by a MyoD family-
belonging myogenin transcription factor [17–19], the observed inhi-
bition of its mRNA expression, as well as its promoter transactivity,
induced by IL-17, conﬁrms a negative action of IL-17 on myogenic dif-
ferentiation. Additionally, our results show that the expression of
myogenic marker protein, MyHC, was severely attenuated by IL-17.
It is known that the skeletal muscle is able to undergo extensive
regeneration and repair after injury through the activation of satellite
cells present in situ leading them to proliferate, migrate to sites of in-
jury and ﬁnally, differentiate into adult muscle cells [29,30]. As IL-17
did not alter cell proliferation, but inhibited the migration of C2C12
cells, it is possible that, in addition to lowering myogenin and MyHC
expression, IL-17 achieves its inhibitory effect on myogenic differen-
tiation by reducing the cell migration capacity, this way preventing
myoblast alignment and fusion, and, consequently the formation of
multinucleated myotubes [29]. The low number of short myotubes
detected when cells were cultured in MDM in the presence of IL-17
is in line with such observation. Nevertheless, further studies are
needed to investigate the role of IL-17 in the cell fusion involved in
myogenic differentiation.
The results concerning the IL-17-dependent induction of osteo-
genesis are consistent with a recent study in which the ability of IL-
17 to promote osteogenic differentiation of human mesenchymal
cells was shown, although the effect on muscle differentiation was
not studied [11]. Additionally, similar was the observation that IL-17
stimulates osteoblastic differentiation independently of its effect on
cell proliferation. As the differentiation process is a sequential event
Fig. 5. IL-17 activates MAPK signaling in C2C12 cells.(A) Activation of ERK1,2, p38 and JNKMAPKs in C2C12 cells cultured in serum-free medium and treated with 100 ng/ml of IL-17
during indicated time intervals, determined byWestern blot. Blots are from the representative experiment, while time course changes of ERK1,2 and p38 MAPK phosphorylation (in
each time point normalized to the control level) are presented as means±SEM from three experiments. Signiﬁcant difference from the control by t-test: *pb0.05. (B) MyHC ex-
pression and ALP activity in C2C12 cells grown in MDM and ODM, respectively, in the absence or presence of p38 MAPK inhibitor, SB203580 (10 μM) and IL-17 (100 ng/ml). (C)
The transactivation of MAPK/ERK reporter (SRE-luc) in transiently transfected C2C12 cells treated with 100 ng/ml IL-17; RLU, relative luciferase units. Signiﬁcant difference
from the control by t-test: ***pb0.001.
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in the rate of cell growthmay result in the increasing level of differen-
tiation. However, since our results did not reveal any effect of IL-17 on
C2C12 proliferation, we can suppose that the cellular effects of IL-17
on the differentiation of C2C12 cells were not due to alterations in
the proliferation rate. Moreover, as IL-17 was shown both by us and
in other reports [11] to be a potent inducer of osteoblastic differenti-
ation in the absence of any additional osteogenic signals, even in the
medium known to promote myogenesis of C2C12 cells, we can postu-
late that the induction of osteogenic differentiation by IL-17 occurs
concurrently with the inhibition of myogenic differentiation. Interest-
ingly, a recent study by Lee et al. [31] demonstrated that IL-17 en-
hances adipogenic differentiation of C2C12 cells under speciﬁc
conditions supporting adipogenesis.Cell commitment to a particular lineage with suppression of alter-
native phenotypes, is governed by speciﬁc cell signaling and activa-
tion of speciﬁc transcription factors [32]. As for Runx2/Cbfa1, it is
well established that this is an essential transcription factor that de-
termines the osteogenic commitment in different cell lineages [33]
and is also known to induce the transdifferentiation of primary skel-
etal myoblasts into an osteoblastic phenotype [34]. Therefore, our
ﬁnding that IL-17 increases Runx2/Cbfa1 expression proposes one
mechanism by which IL-17 may promote osteogenic differentiation
in C2C12 cells. COX-2, an immediate-early response gene induced
mainly at sites of inﬂammation in response to inﬂammatory stimuli
[35], is also required for osteogenic differentiation [36]. The results
presented here, demonstrating that IL-17 induces COX-2 expression
in C2C12 cells, are in line with previously reported data showing
Fig. 6. ERK1,2 signaling pathway mediates IL-17-induced inhibition of myogenesis.C2C12 cells were cultured in MDM in the presence or absence of IL-17 (100 ng/ml) and PD 98059
(25 μM). Levels of MyHC in C2C12 cells determined by (A) immunostaining and (B) Western blot assay; α-tubulin was used as a loading control. (C) Myogenin expression analyzed
by RT-PCR; β-actin was used as a gel loading control. Densitometric quantiﬁcation of the PCR bands±SEM is indicated at the top of images, expressed relative to untreated cells, to
which an arbitrary value of 1 was given, ±SEM given in brackets. Representative results from three independent experiments are shown. Signiﬁcant difference from the control
(untreated cells) by t-test: **pb0.01 (D) The transactivation of G133-luc reporter for myogenin measured by luminometry in transiently transfected C2C12 cells cultured in the
absence or presence of IL-17 (100 ng/ml) and PD 98059 (25 μM) in MDM. The values were normalized to those found in cells grown in control MDM; RLU, relative luciferase
units. Signiﬁcant difference from the control (MDM) by t-test: ***pb0.001.
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goes in parallel with COX-2 increment [11]. However, further studies
are necessary to determine the exact role of COX-2 on the IL-17-
modulated osteogenic differentiation of C2C12 myoblasts.
The interplay between extracellular signals and transcriptional
regulation is a crucial nexus of control for cell lineage determination.
Some of the most commonly studied pathways are the MAPKs [8,21].
MAPKs were shown to be critical for muscle development [37], as
well as for the induction of osteogenic differentiation [29]. In this
context, ERK1,2 MAPK has been reported as an inhibitor of myogenic
differentiation induced by bFGF and TGF-β, and has also been pro-
posed as an essential pathway involved in the decision of mesenchy-
mal cells to differentiate into osteogenic and adipogenic lineage
[21,38–40]. As for IL-17, MAPKs belonging to all three subgroups of
MAPK family were shown to be activated by this cytokine, in various
cell types and in a cell-speciﬁc manner [1–3,41]. In addition, we have
detected the activation of MAPKs, including ERK1,2, by IL-17 in L6E9
myoblast rat cells as well as in primary human MSCs (data not
shown).In this study we demonstrated that both ERK1,2 and p38 MAPK
pathways were activated by IL-17 in C2C12 cells, while no expression
of phosphorylated JNK was observed in both the untreated or IL-17-
treated cells, despite previous reports on the participation of JNK sig-
naling in the myostatin-dependent inhibition of C2C12 cell myogenic
differentiation [42]. By using the p38- and ERK1,2-speciﬁc pharmaco-
logical inhibitors in our further studies we demonstrated that ERK1,2
pathway is more critical for the differentiation commitment elicited
by IL-17 in C2C12 cells. Namely, although IL-17 enhanced the phos-
phorylation of p38 MAPK in C2C12 cells, the inhibition of p38 blocked
both the myogenic and the osteogenic differentiation of these cells,
regardless of the IL-17 presence. This result conﬁrmed that p38 is
an indispensable regulator of the differentiation process towards
both lineages, as demonstrated by previous reports [28,37]. On the
other hand, inhibition of ERK1,2 phosphorylation reverted the inhibi-
tion of myogenic differentiation caused by IL-17 by eliminating the
reduction in the number of myotubes, as well as the reduced expres-
sion of MyHC and myogenin. The inhibition of ERK1,2 MAPK reverted
IL-17-induced osteogenic differentiation as well, by abolishing the
Fig. 7. ERK1,2 signaling pathway mediates IL-17-induced stimulation of osteogenesis.(A) ALP activity detected in C2C12 cells cultured in MDMwith different combinations of IL-17
(100 ng/ml) and PD 98059 (25 μM). (B) The transactivation of p6OSE2-luc reporter for Runx2/Cbfa1 measured by luminometry in transiently transfected C2C12 cells cultured in the
presence or absence of IL-17 (100 ng/ml) and PD 98059 (25 μM) in MDM. The values were normalized to those found in cells grown in control MDM. RLU, relative luciferase units.
Signiﬁcant difference from the control (MDM) by t-test: **pb0.01, *pb0.05. (C) a: Expression of SRE-luc in cells transfected with empty vector (EV) and constitutive active MEK1
(caMEK1), pECE/HA MAPKK, measured by luminometry. Signiﬁcant difference from the control (EV) by t-test: ***pb0.001; insert: HA tagged-MEK1 expression in cells transfected
with EV and caMEK1, determined by Western blot. b: The transactivation of p6OSE2-luc measured by luminometry in C2C12 cells transiently transfected with caMEK1 plasmid,
cultured in GM and MDM. The values were normalized to those found at basal level, in cells transfected with EV. Signiﬁcant difference from the basal level by t-test: ***pb0.001.
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pression of caMEK1 resulted in a signiﬁcant increase of Runx2/Cbfa1
expression, conﬁrming ERK1,2 involvement in osteogenic differentia-
tion induced by IL-17. Consistent with our results, there are previous
studies demonstrating that Runx2/Cbfa1 is controlled by ERK MAPK,
suggesting that this pathway has an important role in the control of
osteoblast-speciﬁc gene expression [43,44]. In terms of differentia-
tion, ERK1,2 has been shown to be important for osteogenesis [45],
chondrogenesis [46], and myogenesis [40], but whether ERK1,2 is
stimulatory or inhibitory to these processes remains unclear due to
the amount of conﬂicting results in the ﬁeld [40]. At the moment
we can speculate that IL-17 might induce osteogenesis by activating
simultaneously both ERK1,2 and p38 intracellular pathways in
C2C12 cells, maintaining a strict balance between these MAPKs, but
when the selective switch in the commitment, either to myogenicor osteogenic lineage, is needed, the activation of ERK1,2 becomes
the key signal responsible. Therefore, the results obtained indicate
that IL-17 through ERK1,2 opens a new signaling mechanism respon-
sible for shifting the commitment of C2C12 cells.
It was previously shown that C2C12 myoblasts can be transdiffer-
entiated into osteoblastic lineage upon BMP stimulation [28]. Canon-
ical BMP signaling is mediated via the ALK1/2/3/6 type I receptors
that phosphorylate Smad1, Smad5, and Smad8 [47]. C2C12 cells ex-
press mainly ALK2, while low expression of ALK3 and ALK6 was ob-
served. Furthermore, it was recently reported that BMP9 can induce
osteogenesis through ALK1 and ALK2 receptors in C2C12 cells [28].
Additionally, BMPRII expression and no BMP-2, BMP-6 and BMP-7 ac-
tivity was detected in C2C12 cells grown in basal culture conditions
[48]. Having this data in mind, our further experiments using ALK2
mutant constructs were aimed to elucidate whether BMP-Smad
Fig. 8. IL-17 induced osteogenic differentiation of C2C12 myoblasts is BMP independent.(A) Ectopic expression of HA-tagged ALK2 in cells transfected with kinase dead (kd) ALK2,
constitutively active (ca) ALK2 or empty vector (ev), and Smad1 phosphorylation determined by Western blot. ns, nonspeciﬁc bands serving as a control for equal loading. (B) The
transactivation of pBRE-luc, reporter for BMP-Smad signaling, in C2C12 cells transfected with empty vector, kd ALK2 and ca ALK2, with and without IL-17 treatment (100 ng/ml).
(C) Cells were transfected with the Gal4-Smad1/pRf5-luc and kd or ca ALK2 plasmids and treated as described in B. (D) The transactivation of Runx2/Cbfa1 reporter in C2C12 cells
transfected and treated as described above. RLU, relative luciferase units. Signiﬁcant difference from the control by t-test: *pb0.05, ***pb0.001. The data presented is representative
of three independent experiments.
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sults obtained demonstrated that there is no activation of BMP-Smad
pathway during IL-17 treatment of C2C12 cells. Moreover, data
obtained after turning the ALK2 receptor, responsible for BMP signal-
ing initiation, “on” and “off” showed that IL-17 activates Runx2/Cbfa1
transcription factor regardless from the activity of ALK2 receptor.
Therefore, we were able to conclude that IL-17-induced osteogenic
differentiation of C2C12 cells is mediated by ERK1,2 independently
of BMP signaling. This conclusion is in line with other reports demon-
strating the existence of BMP-independent mechanisms involved in
the osteogenic differentiation of C2C12 cells [20].
The investigation of IL-17 regulation of the cell commitment into
myogenic or osteogenic lineage might be of importance in the
pathogenesis of inﬂammatory diseases in muscle and bone which
involve the inﬁltration of Th17 cells and IL-17 production, such as poly-
myositis, dermatomyositis and rheumatoid arthritis [14,15,49,50]. The
inﬂammation occurring inmuscle [51,52] can also induce the formation
of ectopic bone, and in all conditions, the presence of multipotent, not
fully committed cells in the tissue is essential [52]. However, there isyet no evidence of IL-17's presence in the inﬂamed muscle during
ectopic bone formation, and we believe that this is a question worth
investigating in the future. According to numerous reports
demonstrating that a major biological function of IL-17 is to act as a
‘ﬁne tuning’ cytokine to enhance or even dampen immune and hemato-
poietic responses [2,6,49], IL-17 can be a part of a regulatory network,
which functions to alter the balance of myoblast cell commitment to
the osteogenic or myogenic lineages. However, IL-17 can also be one
of the candidates thatmight be involved inmuscle destruction inmyop-
athies or in the pathological development of bone in the muscle tissue.
Even though our data, as well as other reports, propose that IL-17 is an
osteoblastic induction agent [11,53], further examinations, both in vivo
and in vitro are needed to support this hypothesis.
Several lines of evidence presented here support the notion that
IL-17 can regulate both the myogenic and osteogenic differentiation
of C2C12 cells, as IL-17-dependent inhibition of myogenesis was asso-
ciated with the down-regulation of the myogeninmRNA levels, MyHC
expression and myotube formation, while IL-17-dependent induction
of osteogenesis was associated with the up-regulation of the Runx2/
Fig. 9. Summary.IL-17 modulates the multilineage commitment of C2C12 cells by inhi-
biting their myogenic differentiation through myogenin and MyHC expression down-
regulation and promoting their differentiation to osteogenic lineage, by up-regulating
Runx2/Cbfa1 and COX-2 expression. The differentiation switch elicited by IL-17 is me-
diated through the activation of ERK1,2 MAPK.
848 J. Kocić et al. / Biochimica et Biophysica Acta 1823 (2012) 838–849Cbfa1 mRNA level, COX-2 expression and ALP activity (Fig. 9). The
data also reveal that IL-17 exerts these effects by activating ERK1,2
MAPK signaling pathway, independently from BMP-Smad signaling.
In conclusion, these data suggest that IL-17 modulates myoblast cell
commitment in vitro by inducing osteogenic while inhibiting myo-
genic differentiation.
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